Trial Profile
A Phase II Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 May 2023
Price :
$35
*
At a glance
- Drugs Sapanisertib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 03 Feb 2022 Status changed from recruiting to active, no longer recruiting.
- 13 Feb 2021 Results assessing (n=38; between August 2017 and November 2019) efficacy and safety of sapanisertib in patients with metastatic renal cell carcinoma progressing on standard therapies, presented at the 2021 Genitourinary Cancers Symposium.
- 07 Dec 2020 Planned primary completion date changed from 25 Aug 2020 to 25 Aug 2021.